Publications from OUS - Translational studies in solid tumors (Helland)

232 publications found

Publications 2025

1. Alver TN, Bergholtz H, Holm MB, Dorg LT, Skrede ML, Kure EH, Verbeke CS (2025)
   Spatial Transcriptomics Reveals Cancer and Stromal Cell Heterogeneity Between Center and Invasive Front of Pancreatic Cancer
   38 (6), 100726
   DOI 10.1016/j.modpat.2025.100726, PubMed 39889965
2. Bergholtz H, Norum JH, Lien TG, Skrede ML, Garred Ø, Sørlie T (2025)
   B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses
   27 (1), 44
   DOI 10.1186/s13058-025-01990-2, PubMed 40119362
3. Førde D, Kilvær T, Pedersen MI, Lombardi AP, D'arsiè I, Paulsen EE, Busund LR, Rakaee M, Dønnem T, Andersen S (2025)
   Prognostic impact of miR-17-5p and miR-20a-5p in NSCLC diverge in subgroups according to lymph node status
   15, 1606933
   DOI 10.3389/fonc.2025.1606933, PubMed 41079079
4. Garcia-Foncillas J, Bayle A, Arnold D, Avouac B, Awada A, de la Cruz-Merino L, Helland Å, Lassen U, Laurent-Puig P, Normanno N, Rohrberg K, Taieb J, Stenzinger A (2025)
   Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access
   21 (14), 1745-1752
   DOI 10.1080/14796694.2025.2501523, PubMed 40340714
5. Hektoen HH, Tsuruda KM, Brustugun OT, Neumann K, Andreassen BK (2025)
   Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression ≥50
   10 (5), 105073
   DOI 10.1016/j.esmoop.2025.105073, PubMed 40305908
6. Henkel PS, Aas E, Russnes HG, Dyvik I, Fagereng GL, Helland Å, Røgenes H, Lien TG, Pedersen K (2025)
   Microcosting Study of Genomic Profiling for Precision Cancer Medicine: Application from the National Infrastructure for Precision Diagnostics in Norway
   27 (10), 945-953
   DOI 10.1016/j.jmoldx.2025.06.006, PubMed 40712993
7. Hermansen JU, Athanasiadis P, Yin Y, Rise AF, Arribas AJ, Cascione L, Russnes HG, Helland Å, Mato AR, Bertoni F, Tjønnfjord GE, Aittokallio T, Skånland SS (2025)
   Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient
   16 (1), 555
   DOI 10.1038/s41419-025-07884-7, PubMed 40701968
8. Horndalsveen H, Haakensen VD, Madebo T, Grønberg BH, Halvorsen TO, Koivunen J, Oselin K, Cicenas S, Helbekkmo N, Aanerud M, Ahvonen J, Silvoniemi M, Bjaanæs MM, Farooqi S, Nebdal D, Dalsgaard AM, Danielsen BK, Børve M, Dalen TS, Öjlert ÅK, Helland Å (2025)
   Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab
   15, 1681420
   DOI 10.3389/fonc.2025.1681420, PubMed 41199847
9. Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC et al. (2025)
   Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
   16 (1), 7717
   DOI 10.1038/s41467-025-63091-0, PubMed 40830141
10. Nyen JE, Booth AØ, Husby Ø, Bugge C, Engebretsen I, Oteiza F, Helland Å, Fjellbirkeland L, Brustugun OT, Grønberg BH (2025)
    Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients - a nationwide and longitudinal study
    15, 1506041
    DOI 10.3389/fonc.2025.1506041, PubMed 40052133
11. Nyen JE, Booth AØ, Husby Ø, Bugge C, Engebretsen I, Oteiza F, Helland Å, Fjellbirkeland L, Brustugun OT, Grønberg BH (2025)
    Corrigendum: Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients - a nationwide and longitudinal study
    15, 1595028
    DOI 10.3389/fonc.2025.1595028, PubMed 40206591
12. Pagui ECK, Brant SB, Svendsen K, Frigessi A, Helland Å, Thoresen S, Jonasson C (2025)
    Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer
    34 (7), e70181
    DOI 10.1002/pds.70181, PubMed 40552731
13. Rakaee M, Tafavvoghi M, Ricciuti B, Alessi JV, Cortellini A, Citarella F, Nibid L, Perrone G, Adib E, Fulgenzi CAM, Hidalgo Filho CM, Di Federico A, Jabar F, Hashemi S, Houda I, Richardsen E, Rasmussen Busund LT, Donnem T, Bahce I, Pinato DJ, Helland Å, Sholl LM, Awad MM, Kwiatkowski DJ (2025)
    Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer
    11 (2), 109-118
    DOI 10.1001/jamaoncol.2024.5356, PubMed 39724105
14. Scheiner B, Lombardi P, D'Alessio A, Kim G, Tafavvoghi M, Petrenko O, Goldin RD, Fulgenzi CAM, Torkpour A, Balcar L, Mauri FA, Pomej K, Himmelsbach V, Barsch M, Celsa C, Cabibbo G, Cheon J, Krall A, Hucke F, Di Tommaso L, Bernasconi M, Rimassa L, Samson A, Stefanini B, Mozayani B et al. (2025)
    Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    13 (10)
    DOI 10.1136/jitc-2024-010975, PubMed 41052886
15. Schytte T, Knap MM, Kristiansen C, Appelt AL, Khalil A, Peucelle C, Lutz CM, Møller DS, Sande EPS, Sundby F, Persson G, Schmidt H, Land LH, Rogg L, Pøhl M, Lund MD, Nielsen M, Levin N, Hansen O, Thing RS, Borissova S, Halvorsen T, Nielsen TB, Hansen TS, Haakensen VD et al. (2025)
    Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial
    43 (17), 1972-1983
    DOI 10.1200/JCO-24-01386, PubMed 40249893
16. Stålberg SM, Silwal-Pandit L, Hamfjord J, Nebdal DJH, Lehtiö J, Lingjærde OC, Skålhegg BS, Kure EH (2025)
    Elevated KRAS protein level is associated with better survival in pancreatic cancer
    25 (1), 1080
    DOI 10.1186/s12885-025-14461-w, PubMed 40596921
17. Tsuruda KM, Hektoen HH, Reis Costa D, Andreassen BK (2025)
    Immortal time bias in survival outcomes when comparing treatment with chemotherapy versus immunochemotherapy for non-small cell lung cancer
    14 (1), 300-302
    DOI 10.21037/tlcr-24-1002, PubMed 39958223
18. Tsuruda KM, Hektoen HH, Aamelfot C, Andreassen BK (2025)
    Let's talk about sex: Survival among females and males in a real-world cohort treated with pembrolizumab for non-small cell lung cancer
    157 (6), 1064-1074
    DOI 10.1002/ijc.35445, PubMed 40298324

Publications 2024

1. Ankill J, Zhao Z, Tekpli X, Kure EH, Kristensen VN, Mathelier A, Fleischer T (2024)
   Integrative pan-cancer analysis reveals a common architecture of dysregulated transcriptional networks characterized by loss of enhancer methylation
   20 (11), e1012565
   DOI 10.1371/journal.pcbi.1012565, PubMed 39556603
2. Bjørgo E, Fagereng GL, Russnes HG, Smeland S, Taskén K, Helland Å (2024)
   Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare
   63, 487-490
   DOI 10.2340/1651-226X.2024.24954, PubMed 38910311
3. Brativnyk A, Ankill J, Helland Å, Fleischer T (2024)
   Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma
   155 (2), 282-297
   DOI 10.1002/ijc.34915, PubMed 38489486
4. Braadland PR, Farnes I, Kure EH, Yaqub S, McCann A, Ueland PM, Labori KJ, Hov JR (2024)
   Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer
   14, 1488749
   DOI 10.3389/fonc.2024.1488749, PubMed 39759130
5. Chen L, Wang X, Xie N, Zhang Z, Xu X, Xue M, Yang Y, Liu L, Su L, Bjaanæs M, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Christiani DC, Chen F, Zhang R (2024)
   A two-phase epigenome-wide four-way gene-smoking interaction study of overall survival for early-stage non-small cell lung cancer
   19 (1), 173-187
   DOI 10.1002/1878-0261.13766, PubMed 39630602
6. Farooqi SJ, Zhao Z, Öjlert ÅK, Thunold S, Juul HV, Bjaanæs MM, Horndalsveen H, Nymoen HMG, Helland Å, Haakensen VD (2024)
   Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma
   15, 1480183
   DOI 10.3389/fimmu.2024.1480183, PubMed 39687621
7. Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjærde OC, Tveit KM, Spindler KG, Pallisgaard N, Kure EH (2024)
   Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer
   24 (2), 153-158
   DOI 10.1016/j.clcc.2024.11.004, PubMed 39743478
8. Hektoen HH, Tsuruda KM, Fjellbirkeland L, Nilssen Y, Brustugun OT, Andreassen BK (2024)
   Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study
   132 (1), 93-102
   DOI 10.1038/s41416-024-02895-1, PubMed 39489879
9. Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K (2024)
   [Raising the quality of cancer treatment]
   144 (1)
   DOI 10.4045/tidsskr.23.0740, PubMed 38258713
10. Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å (2024)
    UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
    202, 113973
    DOI 10.1016/j.ejca.2024.113973, PubMed 38447379
11. Nymoen HM, Alver TN, Horndalsveen H, Eide HA, Bjaanæs MM, Brustugun OT, Grønberg BH, Haakensen VD, Helland Å (2024)
    Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial
    14, 1412716
    DOI 10.3389/fonc.2024.1412716, PubMed 39148905
12. Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å, InPreD Consortium et al. (2024)
    IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
    63, 379-384
    DOI 10.2340/1651-226X.2024.28322, PubMed 38779911
13. Stålberg SM, Silwal-Pandit L, Bastani NE, Nebdal DJH, Lingjærde OC, Skålhegg BS, Kure EH (2024)
    Preoperative profiles of plasma amino acids and derivatives distinguish periampullary cancer and benign disease
    24 (1), 555
    DOI 10.1186/s12885-024-12320-8, PubMed 38702616
14. Tafavvoghi M, Sildnes A, Rakaee M, Shvetsov N, Bongo LA, Busund LR, Møllersen K (2024)
    Deep learning-based classification of breast cancer molecular subtypes from H&E whole-slide images
    16, 100410
    DOI 10.1016/j.jpi.2024.100410, PubMed 39720418
15. Taskén K, Haj Mohammad SF, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H et al. (2024)
    PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
    63, 385-391
    DOI 10.2340/1651-226X.2024.34791, PubMed 38779910
16. Thunold S, Hernes E, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Mikalsen LTG, Helland Å, Malinen E, Haakensen VD (2024)
    Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine
    52 (2), 693-707
    DOI 10.1007/s00259-024-06853-0, PubMed 39133306

Publications 2023

1. Børø S, Thoresen S, Boge Brant S, Helland Å (2023)
   Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancer
   62 (12), 1642-1648
   DOI 10.1080/0284186X.2023.2264484, PubMed 37801361
2. Langberg CW, Horndalsveen H, Helland Å, Haakensen VD (2023)
   Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
   13, 1217424
   DOI 10.3389/fonc.2023.1217424, PubMed 37476372
3. Le Tourneau C, André F, Helland Å, Mileshkin L, Minnaard W, Schiel A, Taskén K, Thomas DM, Veronese ML, Durán-Pacheco G, Leyens L, Rufibach K, Thomas M, Krämer A (2023)
   Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
   194, 113278
   DOI 10.1016/j.ejca.2023.113278, PubMed 37820553
4. Skoie IM, Skogås JG, Langø T, Myhr KM, Myhre PL, Goll R, Fretland SØ, Helland Å (2023)
   New centres to carry out more clinical trials in Norway
   143 (2)
   DOI 10.4045/tidsskr.22.0722, PubMed 36718905

Publications 2022

1. Alver TN, Heintz KM, Hovig E, Bøe SL (2022)
   Cooperative induction of receptor tyrosine kinases contributes to adaptive MAPK drug resistance in melanoma through the PI3K pathway
   6 (2), e1736
   DOI 10.1002/cnr2.1736, PubMed 36251678
2. Berg J, Halvorsen AR, Bengtson MB, Lindberg M, Halvorsen B, Aukrust P, Helland Å, Ueland T (2022)
   Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer
   13, 875152
   DOI 10.3389/fimmu.2022.875152, PubMed 35911763
3. Berg J, Halvorsen AR, Bengtson MB, Lindberg M, Halvorsen B, Aukrust P, Helland Å, Ueland T (2022)
   Corrigendum: Circulating T cell activation and exhaustion markers are associated with radiation pneumonitis and poor survival in non-small-cell lung cancer
   13, 1051156
   DOI 10.3389/fimmu.2022.1051156, PubMed 36263024
4. Børø S, Thoresen S, Helland Å (2022)
   Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 - 2020 - A population-based registry study from Norway
   12, 1017902
   DOI 10.3389/fonc.2022.1017902, PubMed 36523970
5. Callesen LB, Hamfjord J, Boysen AK, Pallisgaard N, Guren TK, Kure EH, Spindler KG (2022)
   Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
   127 (3), 500-513
   DOI 10.1038/s41416-022-01816-4, PubMed 35440666
6. Chen J, Song Y, Li Y, Wei Y, Shen S, Zhao Y, You D, Su L, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Shen H, Christiani DC, Zhang R, Chen F (2022)
   A trans-omics assessment of gene-gene interaction in early-stage NSCLC
   17 (1), 173-187
   DOI 10.1002/1878-0261.13345, PubMed 36408734
7. Eide IJZ, Stensgaard S, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Sørensen BS, Brustugun OT (2022)
   Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
   11 (6), 953-963
   DOI 10.21037/tlcr-21-995, PubMed 35832438
8. Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B (2022)
   Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
   18 (2), 181-193
   DOI 10.1016/j.jtho.2022.10.003, PubMed 36307040
9. Gulati G, Tjessem KH, Horndalsveen H, Halvorsen S, Haakensen VD (2022)
   [Checkpoint inhibitor-induced myocarditis]
   142 (18)
   DOI 10.4045/tidsskr.21.0817, PubMed 36511752
10. Helland Å, Andersen KK, Myklebust TÅ, Johannesen TB, Aarøe J, Enerly E (2022)
    EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study
    33, 100636
    DOI 10.1016/j.ctarc.2022.100636, PubMed 36155129
11. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
    Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
    20 (1), 225
    DOI 10.1186/s12967-022-03432-5, PubMed 35568909
12. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
    Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
    20 (1), 317
    DOI 10.1186/s12967-022-03518-0, PubMed 35841045
13. Horndalsveen H, Alver TN, Dalsgaard AM, Rogg LV, Helbekkmo N, Grønberg BH, Halvorsen TO, Ramberg C, Haakensen VD, Öjlert ÅK, Bjaanaes MM, Helland Å (2022)
    Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial
    17 (3), 487-498
    DOI 10.1002/1878-0261.13330, PubMed 36330681
14. Ji X, Lin L, Fan J, Li Y, Wei Y, Shen S, Su L, Shafer A, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Zhang R, Chen F, Christiani DC (2022)
    Epigenome-wide three-way interaction study identifies a complex pattern between TRIM27, KIAA0226, and smoking associated with overall survival of early-stage NSCLC
    16 (3), 717-731
    DOI 10.1002/1878-0261.13167, PubMed 34932879
15. Khadse A, Haakensen VD, Silwal-Pandit L, Hamfjord J, Micke P, Botling J, Brustugun OT, Lingjærde OC, Helland Å, Kure EH (2022)
    Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
    12, 873532
    DOI 10.3389/fonc.2022.873532, PubMed 35574381
16. Maggadóttir SM, Kvalheim G, Wernhoff P, Sæbøe-Larssen S, Revheim ME, Josefsen D, Wälchli S, Helland Å, Inderberg EM (2022)
    A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
    12, 1031232
    DOI 10.3389/fonc.2022.1031232, PubMed 36439452
17. Silwal-Pandit L, Stålberg SM, Johansson HJ, Mermelekas G, Lothe IMB, Skrede ML, Dalsgaard AM, Nebdal DJH, Helland Å, Lingjærde OC, Labori KJ, Skålhegg BS, Lehtiö J, Kure EH (2022)
    Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
    2 (6), 434-446
    DOI 10.1158/2767-9764.CRC-21-0100, PubMed 36923555
18. Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
    A national precision cancer medicine implementation initiative for Norway
    28 (5), 885-887
    DOI 10.1038/s41591-022-01777-4, PubMed 35513529
19. Umu SU, Langseth H, Zuber V, Helland Å, Lyle R, Rounge TB (2022)
    Serum RNAs can predict lung cancer up to 10 years prior to diagnosis
    11
    DOI 10.7554/eLife.71035, PubMed 35147498

Publications 2021

1. Berg J, Ramberg C, Haugstvedt JOS, Bengtson MB, Gabrielsen AM, Brustugun OT, Halvorsen AR, Helland Å (2021)
   Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
   11, 674731
   DOI 10.3389/fonc.2021.674731, PubMed 34109123
2. Bjaanæs MM, Nilsen G, Halvorsen AR, Russnes HG, Solberg S, Jørgensen L, Brustugun OT, Lingjærde OC, Helland Å (2021)
   Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
   21 (1), 1089
   DOI 10.1186/s12885-021-08811-7, PubMed 34625038
3. Bjaanæs MM, Sande EPS, Loe Ø, Ramberg C, Næss TM, Ottestad A, Rogg LV, Svestad JG, Haakensen VD (2021)
   Improved adaptive radiotherapy to adjust for anatomical alterations during curative treatment for locally advanced lung cancer
   18, 51-54
   DOI 10.1016/j.phro.2021.04.003, PubMed 34258408
4. Eide IJZ, Grut H, Helland Å, Ekman S, Sørensen JB, Hansen KH, Grønberg BH, Cicenas S, Koivunen JP, Mellemgaard A, Brustugun OT (2021)
   Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
   60 (12), 1565-1571
   DOI 10.1080/0284186X.2021.1973092, PubMed 34486915
5. Farooqi SJ, Bjaanæs MM, Helland Å, Haakensen VD (2021)
   [Immunotherapy for malignant pleural mesothelioma]
   141
   DOI 10.4045/tidsskr.21.0503, PubMed 34505475
6. Farooqi SJ, Helland A, Haakensen VD, Bjaanaes MM (2021)
   Immunotherapy in malignant pleural mesothelioma
   Tidsskr. Nor. Laegeforen., 141 (12), 1167-1169
7. Frafjord A, Buer L, Hammarström C, Aamodt H, Woldbæk PR, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2021)
   The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
   12, 764596
   DOI 10.3389/fimmu.2021.764596, PubMed 34868011
8. Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjaerde OC, Tveit KM, Pallisgaard N, Spindler KG, Kure EH (2021)
   Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
   149 (6), 1385-1397
   DOI 10.1002/ijc.33672, PubMed 33961700
9. Hamfjord J, Myklebust TÅ, Larsen IK, Kure EH, Glimelius B, Guren TK, Tveit KM, Guren MG (2021)
   Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
   31 (2), 342-351
   DOI 10.1158/1055-9965.EPI-21-0555, PubMed 34853022
10. Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å (2021)
    NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
    19 (1), 232
    DOI 10.1186/s12967-021-02905-3, PubMed 34059094
11. Johannesen TB, Smeland S, Aaserud S, Buanes EA, Skog A, Ursin G, Helland A (2021)
    COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway
    Front. Oncol., 11, 652535
    DOI 10.3389/fonc.2021.652535
12. Lehtiö J, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, Umer HM, Mermelekas G, Pirmoradian M, Jönsson M, Brunnström H, Brustugun OT, Purohit KP, Cunningham R, Foroughi Asl H, Isaksson S, Arbajian E, Aine M, Karlsson A, Kotevska M, Gram Hansen C, Drageset Haakensen V, Helland Å, Tamborero D, Johansson HJ et al. (2021)
    Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms
    2 (11), 1224-1242
    DOI 10.1038/s43018-021-00259-9, PubMed 34870237
13. Terkelsen T, Pernemalm M, Gromov P, Børresen-Dale AL, Krogh A, Haakensen VD, Lethiö J, Papaleo E, Gromova I (2021)
    High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers
    15 (2), 429-461
    DOI 10.1002/1878-0261.12850, PubMed 33176066
14. Öjlert ÅK, Nebdal D, Snapkov I, Olsen V, Kidman J, Greiff V, Chee J, Helland Å (2021)
    Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor
    15 (11), 2958-2968
    DOI 10.1002/1878-0261.13082, PubMed 34402187

Publications 2020

1. Abravan A, Eide HA, Helland Å, Malinen E (2020)
   Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
   22, 15-21
   DOI 10.1016/j.ctro.2020.02.005, PubMed 32181373
2. Brustugun OT, Sorhaug S, Gronberg BH, Aanerud M, Al-Zubayidy MMZ, Fjellbirkeland L, Helland A, Berg J, Andreassen B, Paulsen EE, Haram PM, Ashraf H, Wahl SGF (2020)
   Lung cancer: Improved prognosis presents capacity challenges
   Tidsskr. Nor. Laegeforen., 140 (5), 432-434
3. Eide IJZ, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Brustugun OT (2020)
   Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
   143, 27-35
   DOI 10.1016/j.lungcan.2020.03.009, PubMed 32200138
4. Frafjord A, Skarshaug R, Hammarström C, Stankovic B, Dorg LT, Aamodt H, Woldbaek PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2020)
   Antibody combinations for optimized staining of macrophages in human lung tumours
   92 (1), e12889
   DOI 10.1111/sji.12889, PubMed 32299134
5. Goleva-Fjellet S, Bjurholt AM, Kure EH, Larsen IK, Støren Ø, Sæbø M (2020)
   Distribution of allele frequencies for genes associated with physical activity and/or physical capacity in a homogenous Norwegian cohort- a cross-sectional study
   21 (1), 8
   DOI 10.1186/s12863-020-0813-1, PubMed 31973699
6. Halvorsen AR, Haugen MH, Öjlert ÅK, Lund-Iversen M, Jørgensen L, Solberg S, Mælandsmo GM, Brustugun OT, Helland Å (2020)
   Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
   10, 590755
   DOI 10.3389/fonc.2020.590755, PubMed 33324562
7. Haakensen VD, Khadse A, Sandhu V, Halvorsen AR, Solberg SK, Jørgensen LH, Brustugun OT, Kure EH, Helland Å (2020)
   Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
   147 (10), 2957-2966
   DOI 10.1002/ijc.33121, PubMed 32468587
8. Ji X, Lin L, Shen S, Dong X, Chen C, Li Y, Zhu Y, Huang H, Chen J, Chen X, Wei L, He J, Duan W, Su L, Jiang Y, Fan J, Guan J, You D, Shafer A, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M et al. (2020)
   Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients
   14 (11), 2759-2774
   DOI 10.1002/1878-0261.12785, PubMed 33448640
9. Stankovic B, Aamodt H, Bjørhovde HAK, Müller E, Hammarström C, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2020)
   The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
   92 (2), e12893
   DOI 10.1111/sji.12893, PubMed 32433774
10. Terkelsen T, Russo F, Gromov P, Haakensen VD, Brunak S, Gromova I, Krogh A, Papaleo E (2020)
    Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration
    22 (1), 73
    DOI 10.1186/s13058-020-01295-6, PubMed 32605588
11. Umu SU, Langseth H, Keller A, Meese E, Helland Å, Lyle R, Rounge TB (2020)
    A 10-year prediagnostic follow-up study shows that serum RNA signals are highly dynamic in lung carcinogenesis
    14 (2), 235-247
    DOI 10.1002/1878-0261.12620, PubMed 31851411
12. Zhang R, Chen C, Dong X, Shen S, Lai L, He J, You D, Lin L, Zhu Y, Huang H, Chen J, Wei L, Chen X, Li Y, Guo Y, Duan W, Liu L, Su L, Shafer A, Fleischer T, Moksnes Bjaanæs M, Karlsson A, Planck M, Wang R, Staaf J et al. (2020)
    Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects
    158 (2), 808-819
    DOI 10.1016/j.chest.2020.01.048, PubMed 32113923
13. Öjlert ÅK, Nebdal D, Lund-Iversen M, Åstrøm Ellefsen R, Brustugun OT, Gran JM, Halvorsen AR, Helland Å (2020)
    Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy
    60 (2), 149-156
    DOI 10.1080/0284186X.2020.1854851, PubMed 33356733

Publications 2019

1. Abravan A, Eide HA, Løndalen AM, Helland Å, Malinen E (2019)
   Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer
   21 (2), 391-398
   DOI 10.1007/s11307-018-1226-7, PubMed 29916117
2. Bergholtz H, Lien TG, Ursin G, Holmen MM, Helland Å, Sørlie T, Haakensen VD (2019)
   A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue
   24 (2), 163-175
   DOI 10.1007/s10911-018-09423-x, PubMed 30613869
3. Bowitz Lothe IM, Kleive D, Pomianowska E, Cvancarova M, Kure E, Dueland S, Gladhaug IP, Labori KJ (2019)
   Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy
   19 (2), 316-324
   DOI 10.1016/j.pan.2019.01.019, PubMed 30713128
4. Dong X, Zhang R, He J, Lai L, Alolga RN, Shen S, Zhu Y, You D, Lin L, Chen C, Zhao Y, Duan W, Su L, Shafer A, Salama M, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Wang R, Staaf J, Helland Å, Esteller M, Wei Y, Chen F et al. (2019)
   Trans-omics biomarker model improves prognostic prediction accuracy for early-stage lung adenocarcinoma
   11 (16), 6312-6335
   DOI 10.18632/aging.102189, PubMed 31434796
5. Halvorsen AR, Ragle Aure M, Õjlert ÅK, Brustugun OT, Solberg S, Nebdal D, Helland Å (2019)
   Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
   13 (12), 2604-2615
   DOI 10.1002/1878-0261.12571, PubMed 31505091
6. Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG (2019)
   Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
   30 (7), 1088-1095
   DOI 10.1093/annonc/mdz139, PubMed 31046124
7. Nygård S, Lingjærde OC, Caldas C, Hovig E, Børresen-Dale AL, Helland Å, Haakensen VD (2019)
   PathTracer: High-sensitivity detection of differential pathway activity in tumours
   9 (1), 16332
   DOI 10.1038/s41598-019-52529-3, PubMed 31704995
8. Sandhu V, Labori KJ, Borgida A, Lungu I, Bartlett J, Hafezi-Bakhtiari S, Denroche RE, Jang GH, Pasternack D, Mbaabali F, Watson M, Wilson J, Kure EH, Gallinger S, Haibe-Kains B (2019)
   Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma
   3, 1-16
   DOI 10.1200/CCI.18.00102, PubMed 31070984
9. Shao B, Bjaanæs MM, Helland Å, Schütte C, Conrad T (2019)
   EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma
   14 (1), e0204186
   DOI 10.1371/journal.pone.0204186, PubMed 30703089
10. Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2019)
    Immune Cell Composition in Human Non-small Cell Lung Cancer
    9, 3101
    DOI 10.3389/fimmu.2018.03101, PubMed 30774636
11. Zhang R, Lai L, Dong X, He J, You D, Chen C, Lin L, Zhu Y, Huang H, Shen S, Wei L, Chen X, Guo Y, Liu L, Su L, Shafer A, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Wei Y et al. (2019)
    SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomic-smoking interaction analysis
    13 (5), 1235-1248
    DOI 10.1002/1878-0261.12482, PubMed 30924596
12. Zhang R, Lai L, He J, Chen C, You D, Duan W, Dong X, Zhu Y, Lin L, Shen S, Guo Y, Su L, Shafer A, Moran S, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Wei Y, Chen F, Christiani DC (2019)
    EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC
    14 (2), 118-129
    DOI 10.1080/15592294.2019.1573066, PubMed 30665327
13. Öjlert ÅK, Halvorsen AR, Nebdal D, Lund-Iversen M, Solberg S, Brustugun OT, Lingjaerde OC, Helland Å (2019)
    The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery
    13 (5), 1166-1179
    DOI 10.1002/1878-0261.12475, PubMed 30854794

Publications 2018

1. Berg J, Halvorsen AR, Bengtson MB, Taskén KA, Mælandsmo GM, Yndestad A, Halvorsen B, Brustugun OT, Aukrust P, Ueland T, Helland Å (2018)
   Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
   18 (1), 739
   DOI 10.1186/s12885-018-4659-0, PubMed 30005623
2. Eide HA, Knudtsen IS, Sandhu V, Løndalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland Å (2018)
   Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
   3 (2), 130-138
   DOI 10.1016/j.adro.2017.12.007, PubMed 29904737
3. Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L (2018)
   Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
   13 (12), 1906-1918
   DOI 10.1016/j.jtho.2018.08.2027, PubMed 30217492
4. Guo Y, Zhang R, Shen S, Wei Y, Salama SM, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Su L, Zhu Z, Staaf J, Helland Å, Esteller M, Christiani DC (2018)
   DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients
   27 (12), 1527-1535
   DOI 10.1158/1055-9965.EPI-18-0454, PubMed 30185536
5. Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT, Helland Å (2018)
   Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
   57 (9), 1225-1231
   DOI 10.1080/0284186X.2018.1465585, PubMed 29683761
6. Helland A (2018)
   Groundbreaking basic research
   Tidsskr. Nor. Laegeforen., 138 (20), 1905
7. Jabeen S, Espinoza JA, Torland LA, Zucknick M, Kumar S, Haakensen VD, Lüders T, Engebraaten O, Børresen-Dale AL, Kyte JA, Gromov P, Naume B, Kristensen V, Gromova I, Tekpli X (2018)
   Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
   8 (2), e1537691
   DOI 10.1080/2162402X.2018.1537691, PubMed 30713794
8. Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, Polyak K, Børresen-Dale AL, Helland Å, Markowetz F, Russnes HG (2018)
   Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors
   12 (11), 1838-1855
   DOI 10.1002/1878-0261.12375, PubMed 30133130
9. Shen S, Zhang R, Guo Y, Loehrer E, Wei Y, Zhu Y, Yuan Q, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Su L, Chen F, Christiani DC (2018)
   A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer
   12 (6), 913-924
   DOI 10.1002/1878-0261.12204, PubMed 29656435
10. Terkelsen T, Haakensen VD, Saldova R, Gromov P, Hansen MK, Stöckmann H, Lingjaerde OC, Børresen-Dale AL, Papaleo E, Helland Å, Rudd PM, Gromova I (2018)
    N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome
    12 (6), 972-990
    DOI 10.1002/1878-0261.12312, PubMed 29698574
11. Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, Pfeiffer P, Kure EH, Johansen JS, Tveit KM, Christoffersen T, Guren TK (2018)
    Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
    118 (12), 1609-1616
    DOI 10.1038/s41416-018-0115-9, PubMed 29872151
12. Wei Y, Liang J, Zhang R, Guo Y, Shen S, Su L, Lin X, Moran S, Helland Å, Bjaanæs MM, Karlsson A, Planck M, Esteller M, Fleischer T, Staaf J, Zhao Y, Chen F, Christiani DC (2018)
    Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC
    10, 41
    DOI 10.1186/s13148-018-0474-3, PubMed 29619118

Publications 2017

1. Abravan A, Eide HA, Knudtsen IS, Løndalen AM, Helland Å, Malinen E (2017)
   Assessment of pulmonary ¹⁸F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib
   4, 57-63
   DOI 10.1016/j.ctro.2017.04.002, PubMed 29594209
2. Abravan A, Knudtsen IS, Eide HA, Løndalen AM, Helland Å, van Luijk P, Malinen E (2017)
   A new method to assess pulmonary changes using ¹⁸F-fluoro-2-deoxyglucose positron emission tomography for lung cancer patients following radiotherapy
   56 (11), 1597-1603
   DOI 10.1080/0284186X.2017.1349336, PubMed 28849707
3. Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG (2017)
   Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
   8 (34), 57121-57133
   DOI 10.18632/oncotarget.19078, PubMed 28915659
4. Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN (2017)
   DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
   8 (1), 1074-1082
   DOI 10.18632/oncotarget.13718, PubMed 27911866
5. Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM (2017)
   Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
   116 (10), 1271-1278
   DOI 10.1038/bjc.2017.93, PubMed 28399112
6. Halvorsen AR, Kristensen G, Embleton A, Adusei C, Barretina-Ginesta MP, Beale P, Helland Å (2017)
   Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients
   2017, 3098542
   DOI 10.1155/2017/3098542, PubMed 28293063
7. Mezheyeuski A, Strell C, Hrynchyk I, Guren TK, Dragomir A, Doroshenko T, Pashkova O, Gorgun J, Ruksha K, Pfeiffer P, Kure EH, Sorbye H, Edler D, Martling A, Glimelius B, Östman A, Portyanko A (2017)
   Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer
   472 (3), 395-405
   DOI 10.1007/s00428-017-2263-3, PubMed 29134439
8. Saldova R, Haakensen VD, Rødland E, Walsh I, Stöckmann H, Engebraaten O, Børresen-Dale AL, Rudd PM (2017)
   Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up
   11 (10), 1361-1379
   DOI 10.1002/1878-0261.12105, PubMed 28657165
9. Thomsen M, Guren MG, Skovlund E, Glimelius B, Hjermstad MJ, Johansen JS, Kure E, Sorbye H, Pfeiffer P, Christoffersen T, Guren TK, Tveit KM (2017)
   Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
   81, 26-35
   DOI 10.1016/j.ejca.2017.04.026, PubMed 28595137

Publications 2016

1. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Hills M, Jarosz M, Drury S, Canisius S, Bolla MK, Dennis J et al. (2016)
   Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170
   48 (4), 374-86
   DOI 10.1038/ng.3521, PubMed 26928228
2. Eide HA, Halvorsen AR, Bjaanæs MM, Piri H, Holm R, Solberg S, Jørgensen L, Brustugun OT, Kiserud CE, Helland Å (2016)
   The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes
   16, 71
   DOI 10.1186/s12885-016-2104-9, PubMed 26858029
3. Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å (2016)
   Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
   5 (11), e109
   DOI 10.1038/cti.2016.65, PubMed 27990285
4. Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, Møller Talman ML, Brunner N, Børresen-Dale AL, Gromov P, Helland Å, Kristensen VN, Gromova I (2016)
   Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics
   5 (12), e1248015
   DOI 10.1080/2162402X.2016.1248015, PubMed 28123884
5. Halvorsen AR, Bjaanæs M, LeBlanc M, Holm AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC, López-Guerrero JA, Brustugun OT, Helland Å (2016)
   A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
   7 (24), 37250-37259
   DOI 10.18632/oncotarget.9363, PubMed 27191990
6. Halvorsen AR, Helland Å, Gromov P, Wielenga VT, Talman MM, Brunner N, Sandhu V, Børresen-Dale AL, Gromova I, Haakensen VD (2016)
   Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer
   11 (2), 220-234
   DOI 10.1002/1878-0261.12025, PubMed 28145100
7. Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å (2016)
   TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
   7, 85
   DOI 10.3389/fgene.2016.00085, PubMed 27242894
8. Helland A (2016)
   MicroRNA-profiles in lung adenocarcinomas
   Expert Rev. Precis. Med. Drug Dev., 1 (5), 469-474
   DOI 10.1080/23808993.2016.1240011
9. Haakensen VD, Nygaard V, Greger L, Aure MR, Fromm B, Bukholm IR, Lüders T, Chin SF, Git A, Caldas C, Kristensen VN, Brazma A, Børresen-Dale AL, Hovig E, Helland Å (2016)
   Subtype-specific micro-RNA expression signatures in breast cancer progression
   139 (5), 1117-28
   DOI 10.1002/ijc.30142, PubMed 27082076
10. Joly-Battaglini A, Hammarström C, Stankovic B, Aamodt H, Stjärne J, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2016)
    Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
    5, 38
    DOI 10.12688/f1000research.7599.1, PubMed 27081474
11. Kongsgaard A, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM (2016)
    Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
    11 (1), 50
    DOI 10.1186/s13000-016-0504-4, PubMed 27316334
12. McGowan M, Hoven AS, Lund-Iversen M, Solberg S, Helland Å, Hirsch FR, Brustugun OT (2016)
    PIK3CA mutations as prognostic factor in squamous cell lung carcinoma
    103, 52-57
    DOI 10.1016/j.lungcan.2016.11.018, PubMed 28024696
13. Mezheyeuski A, Bradic Lindh M, Guren TK, Dragomir A, Pfeiffer P, Kure EH, Ikdahl T, Skovlund E, Corvigno S, Strell C, Pietras K, Ponten F, Mulder J, Qvortrup C, Portyanko A, Tveit KM, Glimelius B, Sorbye H, Östman A (2016)
    Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
    7 (27), 41948-41958
    DOI 10.18632/oncotarget.9632, PubMed 27248825
14. Sandhu V, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH (2016)
    The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma
    76 (17), 5092-102
    DOI 10.1158/0008-5472.CAN-16-0658, PubMed 27488532
15. Tarpgaard LS, Ørum-Madsen MS, Christensen IJ, Nordgaard C, Noer J, Guren TK, Glimelius B, Sorbye H, Ikdahl T, Kure EH, Tveit KM, Nielsen HJ, Pfeiffer P, Brünner N, Moreira JM (2016)
    TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer
    7 (37), 59441-59457
    DOI 10.18632/oncotarget.11118, PubMed 27509063
16. Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, Johansen JS, Kure EH, Ikdahl T, Tveit KM, Christoffersen T, Guren TK (2016)
    Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
    7 (46), 75013-75022
    DOI 10.18632/oncotarget.12601, PubMed 27738330
17. Weischenfeldt J, Dubash T, Drainas AP, Mardin BR, Chen Y, Stütz AM, Waszak SM, Bosco G, Halvorsen AR, Raeder B, Efthymiopoulos T, Erkek S, Siegl C, Brenner H, Brustugun OT, Dieter SM, Northcott PA, Petersen I, Pfister SM, Schneider M, Solberg SK, Thunissen E, Weichert W, Zichner T, Thomas R et al. (2016)
    Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking
    49 (1), 65-74
    DOI 10.1038/ng.3722, PubMed 27869826

Publications 2015

1. Andersen V, Vogel LK, Kopp TI, Sæbø M, Nonboe AW, Hamfjord J, Kure EH, Vogel U (2015)
   High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence
   10 (3), e0119255
   DOI 10.1371/journal.pone.0119255, PubMed 25793771
2. Baekelandt BM, Hjermstad MJ, Nordby T, Fagerland MW, Kure EH, Heiberg T, Buanes T, Labori KJ (2015)
   Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma
   18 (3), 247-54
   DOI 10.1016/j.hpb.2015.09.004, PubMed 27017164
3. Berg J, Fjellbirkeland L, Suhrke P, Jebsen P, Lund-Iversen M, Kleinberg L, Helgeland L, Brustugun OT, Helland Å (2015)
   EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust
   55 (2), 149-55
   DOI 10.3109/0284186X.2015.1062537, PubMed 26313507
4. Bjaanæs MM, Fleischer T, Halvorsen AR, Daunay A, Busato F, Solberg S, Jørgensen L, Kure E, Edvardsen H, Børresen-Dale AL, Brustugun OT, Tost J, Kristensen V, Helland Å (2015)
   Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
   10 (2), 330-43
   DOI 10.1016/j.molonc.2015.10.021, PubMed 26601720
5. Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, García-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH et al. (2015)
   Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
   17 (6), 816-26
   DOI 10.1038/ncb3169, PubMed 25985394
6. Darabi H, McCue K, Beesley J, Michailidou K, Nord S, Kar S, Humphreys K, Thompson D, Ghoussaini M, Bolla MK, Dennis J, Wang Q, Canisius S, Scott CG, Apicella C, Hopper JL, Southey MC, Stone J, Broeks A, Schmidt MK, Scott RJ, Lophatananon A, Muir K, Beckmann MW, Ekici AB et al. (2015)
   Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
   97 (1), 22-34
   DOI 10.1016/j.ajhg.2015.05.002, PubMed 26073781
7. Hamfjord J, Saldova R, Stöckmann H, Sandhu V, Bowitz Lothe IM, Buanes T, Lingjærde OC, Labori KJ, Rudd PM, Kure EH (2015)
   Serum N-Glycome Characterization in Patients with Resectable Periampullary Adenocarcinoma
   14 (12), 5144-56
   DOI 10.1021/acs.jproteome.5b00395, PubMed 26515733
8. Helland A (2015)
   Gene jockeys Life science and the rise of biotech enterprise.
   Tidsskr. Nor. Laegeforen., 135 (4), 356
   DOI 10.4045/tidsskr.14.1367
9. Helland A (2015)
   Cancer stem cells
   Tidsskr. Nor. Laegeforen., 135 (8), 783
   DOI 10.4045/tidsskr.15.0031
10. Helland A (2015)
    Viruses and human cancer
    Tidsskr. Nor. Laegeforen., 135 (9), 874
    DOI 10.4045/tidsskr.15.0167
11. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K et al. (2015)
    Tumour exosome integrins determine organotropic metastasis
    527 (7578), 329-35
    DOI 10.1038/nature15756, PubMed 26524530
12. Haakensen VD, Steinfeld I, Saldova R, Shehni AA, Kifer I, Naume B, Rudd PM, Børresen-Dale AL, Yakhini Z (2015)
    Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome
    10 (1), 59-72
    DOI 10.1016/j.molonc.2015.08.002, PubMed 26321095
13. Kjersem JB, Thomsen M, Guren T, Hamfjord J, Carlsson G, Gustavsson B, Ikdahl T, Indrebø G, Pfeiffer P, Lingjærde O, Tveit KM, Wettergren Y, Kure EH (2015)
    AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
    16 (3), 272-9
    DOI 10.1038/tpj.2015.54, PubMed 26261061
14. Labori KJ, Katz MH, Tzeng CW, Bjørnbeth BA, Cvancarova M, Edwin B, Kure EH, Eide TJ, Dueland S, Buanes T, Gladhaug IP (2015)
    Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study
    55 (3), 265-77
    DOI 10.3109/0284186X.2015.1068445, PubMed 26213211
15. Potapenko IO, Lüders T, Russnes HG, Helland Å, Sørlie T, Kristensen VN, Nord S, Lingjærde OC, Børresen-Dale AL, Haakensen VD (2015)
    Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
    9 (4), 861-76
    DOI 10.1016/j.molonc.2014.12.013, PubMed 25655580
16. Sandhu V, Bowitz Lothe IM, Labori KJ, Skrede ML, Hamfjord J, Dalsgaard AM, Buanes T, Dube G, Kale MM, Sawant S, Kulkarni-Kale U, Børresen-Dale AL, Lingjærde OC, Kure EH (2015)
    Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma
    10 (2), 303-16
    DOI 10.1016/j.molonc.2015.10.011, PubMed 26590090
17. Syljuåsen RG, Hasvold G, Hauge S, Helland Å (2015)
    Targeting lung cancer through inhibition of checkpoint kinases
    6, 70
    DOI 10.3389/fgene.2015.00070, PubMed 25774168

Publications 2014

1. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F, Polyak K (2014)
   Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity
   6 (3), 514-27
   DOI 10.1016/j.celrep.2013.12.041, PubMed 24462293
2. Bjaanaes MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Børresen-Dale AL, Brustugun OT, Helland A (2014)
   Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
   135 (8), 1812-21
   DOI 10.1002/ijc.28828, PubMed 24599520
3. Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Wärnberg F, Naume B, Helland A, Børresen-Dale AL, Tost J, Christensen BC, Kristensen VN (2014)
   Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
   15 (8), 435
   DOI 10.1186/PREACCEPT-2333349012841587, PubMed 25146004
4. Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis MLH, Haakensen VD, Warnberg F, Naume B, Helland A, Borresen-Dale AL, Tost J, Christensen BC, Kristensen VN (2014)
   Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
   Genome Biol., 15 (8), 435
   DOI 10.1186/s13059-014-0435-x
5. Halvorsen AR, Helland A, Fleischer T, Haug KM, Grenaker Alnaes GI, Nebdal D, Syljuåsen RG, Touleimat N, Busato F, Tost J, Saetersdal AB, Børresen-Dale AL, Kristensen V, Edvardsen H (2014)
   Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy
   135 (9), 2085-95
   DOI 10.1002/ijc.28862, PubMed 24658971
6. Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH (2014)
   FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
   14, 340
   DOI 10.1186/1471-2407-14-340, PubMed 24884501
7. Saldova R, Asadi Shehni A, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, Helland A, Yakhini Z, Børresen-Dale AL, Rudd PM (2014)
   Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC
   13 (5), 2314-27
   DOI 10.1021/pr401092y, PubMed 24669823
8. Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH (2014)
   Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas
   9 (4), 758-71
   DOI 10.1016/j.molonc.2014.12.002, PubMed 25579086
9. Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM (2014)
   Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
   9 (2), e87746
   DOI 10.1371/journal.pone.0087746, PubMed 24498368
10. Trinh A, Rye IH, Almendro V, Helland A, Russnes HG, Markowetz F (2014)
    GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images
    15 (8), 442
    DOI 10.1186/s13059-014-0442-y, PubMed 25168174
11. Vogel LK, Sæbø M, Høyer H, Kopp TI, Vogel U, Godiksen S, Frenzel FB, Hamfjord J, Bowitz-Lothe IM, Johnson E, Kure EH, Andersen V (2014)
    Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis
    9 (8), e105254
    DOI 10.1371/journal.pone.0105254, PubMed 25166592
12. Wennerström AB, Lothe IM, Sandhu V, Kure EH, Myklebost O, Munthe E (2014)
    Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines
    9 (8), e103873
    DOI 10.1371/journal.pone.0103873, PubMed 25148029

Publications 2013

1. Andersen V, Vogel U, Godiksen S, Frenzel FB, Sæbø M, Hamfjord J, Kure E, Vogel LK (2013)
   Low ABCB1 gene expression is an early event in colorectal carcinogenesis
   8 (8), e72119
   DOI 10.1371/journal.pone.0072119, PubMed 23977225
2. Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL (2013)
   High levels of genomic aberrations in serous ovarian cancers are associated with better survival
   8 (1), e54356
   DOI 10.1371/journal.pone.0054356, PubMed 23372714
3. Choudhury S, Almendro V, Merino VF, Wu ZH, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, Kaspi A, Hu R, Robens J, Nikolskaya T, Haakensen VD, Schnitt SJ, Argani P, Ethington G, Panos L, Grant M et al. (2013)
   Molecular Profiling of Human Mammary Gland Links Breast Cancer Risk to a p27(+) Cell Population with Progenitor Characteristics
   Cell Stem Cell, 13 (1), 117-130
   DOI 10.1016/j.stem.2013.05.004
4. Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH (2013)
   Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment
   8 (1), 59-67
   DOI 10.1016/j.molonc.2013.09.001, PubMed 24119443
5. Kongsgaard A, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM (2013)
   Osteopontin is a prognostic biomarker in non-small cell lung cancer
   13, 540
   DOI 10.1186/1471-2407-13-540, PubMed 24215488
6. Nordby T, Ikdahl T, Bowitz Lothe IM, Fagerland MW, Heiberg T, Hauge T, Labori KJ, Buanes T (2013)
   Improved survival and quality of life in patients undergoing R1 pancreatic resection compared to patients with locally advanced unresectable pancreatic adenocarcinoma
   13 (2), 180-5
   DOI 10.1016/j.pan.2013.01.003, PubMed 23561977
7. Nordgard O, Singh G, Solberg S, Jorgensen L, Halvorsen AR, Smaaland R, Brustugun OT, Helland A (2013)
   Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer
   PLoS One, 8 (5), e62153
   DOI 10.1371/journal.pone.0062153
8. Rajaram M, Zhang JP, Wang T, Li JY, Kuscu C, Qi H, Kato M, Grubor V, Weil RJ, Helland A, Borrenson-Dale AL, Cho KR, Levine DA, Houghton AN, Wolchok JD, Myeroff L, Markowitz SD, Lowe SW, Zhang M, Krasnitz A, Lucito R, Mu D, Powers RS (2013)
   Two Distinct Categories of Focal Deletions in Cancer Genomes
   PLoS One, 8 (6), e66264
   DOI 10.1371/journal.pone.0066264

Publications 2012

1. Brustugun OT, Helland Å, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, Scott H, Dønnem T, Bremnes R, Berg T, Grønberg BH, Dai HY, Wahl SG, Mangseth K, Helgeland L (2012)
   [Mutation testing for non-small-cell lung cancer]
   132 (8), 952-5
   DOI 10.4045/tidsskr.11.1017, PubMed 22562326
2. Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH (2012)
   Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing
   7 (4), e34150
   DOI 10.1371/journal.pone.0034150, PubMed 22529906
3. Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH (2012)
   Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
   12, 534
   DOI 10.1186/1471-2407-12-534, PubMed 23167843
4. Kure EH, Hamfjord J, Stangeland AM, Tveit KM, Ikdahl T (2012)
   KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem
   12 (4), 327-8
   DOI 10.1586/erm.12.29, PubMed 22616697
5. Riis ML, Lüders T, Markert EK, Haakensen VD, Nesbakken AJ, Kristensen VN, Bukholm IR (2012)
   Molecular profiles of pre- and postoperative breast cancer tumours reveal differentially expressed genes
   2012, 450267
   DOI 10.5402/2012/450267, PubMed 23227362
6. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T (2012)
   Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
   30 (15), 1755-62
   DOI 10.1200/JCO.2011.38.0915, PubMed 22473155

Publications 2011

1. Bornholdt J, Friis S, Godiksen S, Poulsen SS, Santoni-Rugiu E, Bisgaard HC, Lothe IM, Ikdahl T, Tveit KM, Johnson E, Kure EH, Vogel LK (2011)
   The level of claudin-7 is reduced as an early event in colorectal carcinogenesis
   11, 65
   DOI 10.1186/1471-2407-11-65, PubMed 21310043
2. Hammerman PS, Sos ML, Ramos AH, Xu CX, Dutt A, Zhou WJ, Brace LE, Woods BA, Lin WC, Zhang JM, Deng XM, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F et al. (2011)
   Mutations in the DDR2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer
   Cancer Discov., 1 (1), 78-89
   DOI 10.1158/2159-8274.CD-11-0005
3. Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ, Australian Ovarian Cancer Study Group, Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD (2011)
   Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers
   6 (4), e18064
   DOI 10.1371/journal.pone.0018064, PubMed 21533284
4. Helland Å, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, Sagerup C, Solberg S, Jørgensen L, Ariansen S, Brustugun OT (2011)
   EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery
   6 (5), 947-50
   DOI 10.1097/JTO.0b013e31820db209, PubMed 21623266
5. Haakensen VD, Bjøro T, Lüders T, Riis M, Bukholm IK, Kristensen VN, Troester MA, Homen MM, Ursin G, Børresen-Dale AL, Helland Å (2011)
   Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas
   11, 332
   DOI 10.1186/1471-2407-11-332, PubMed 21812955
6. Haakensen VD, Lingjaerde OC, Lüders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, Børresen-Dale AL, Helland A (2011)
   Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features
   4, 77
   DOI 10.1186/1755-8794-4-77, PubMed 22044755
7. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL (2011)
   Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
   109 (8), 2802-7
   DOI 10.1073/pnas.1108781108, PubMed 21908711
8. Marcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, Dar I, Jeanneau C, DeFrees S, Krustrup D, Vogel LK, Kure EH, Burchell J, Taylor-Papadimitriou J, Clausen H, Mandel U, Reis CA (2011)
   ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues
   3 (4), 1443-55
   DOI 10.2741/e345, PubMed 21622148
9. Turzer M, Brustugun OT, Waldeland E, Helland A (2011)
   Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidity
   4 (1), 25-34
   DOI 10.1159/000324113, PubMed 21526003

Publications 2010

1. Haakensen VD, Biong M, Lingjærde OC, Holmen MM, Frantzen JO, Chen Y, Navjord D, Romundstad L, Lüders T, Bukholm IK, Solvang HK, Kristensen VN, Ursin G, Børresen-Dale AL, Helland A (2010)
   Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density
   12 (4), R65
   DOI 10.1186/bcr2632, PubMed 20799965
2. Turzer M, Brustugun OT, Helland A (2010)
   Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
   3 (2), 195-201
   DOI 10.1159/000317104, PubMed 20740196

Publications 2009

1. Andersen V, Agerstjerne L, Jensen D, Østergaard M, Saebø M, Hamfjord J, Kure E, Vogel U (2009)
   The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study
   10, 18
   DOI 10.1186/1471-2350-10-18, PubMed 19250544
2. Hansteen IL, Clausen KO, Haugan V, Svendsen M, Svendsen MV, Eriksen JG, Skiaker R, Hauger E, Lågeide L, Vistnes AI, Kure EH (2009)
   Cytogenetic effects of exposure to 2.3 GHz radiofrequency radiation on human lymphocytes in vitro
   29 (11), 4323-30
   PubMed 20032374
3. Hansteen IL, Lageide L, Clausen KO, Haugan V, Svendsen M, Eriksen JG, Skiaker R, Hauger E, Vistnes AI, Kure EH (2009)
   Cytogenetic Effects of 18.0 and 16.5 GHz Microwave Radiation on Human Lymphocytes In Vitro
   Anticancer Res., 29 (8), 2885-2892
4. Hansteen IL, Lågeide L, Clausen KO, Haugan V, Svendsen M, Eriksen JG, Skiaker R, Hauger E, Vistnes AI, Kure EH (2009)
   Cytogenetic effects of 18.0 and 16.5 GHz microwave radiation on human lymphocytes in vitro
   29 (8), 2885-92
   PubMed 19661291
5. Kamalakaran S, Kendall J, Zhao X, Tang C, Khan S, Ravi K, Auletta T, Riggs M, Wang Y, Helland A, Naume B, Dimitrova N, Børresen-Dale AL, Hicks J, Lucito R (2009)
   Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation
   37 (12), e89
   DOI 10.1093/nar/gkp413, PubMed 19474344
6. Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SMF, Ciotti M, Das BR, Del Mistro A, Dybikowska A, Giuliano AR, Gudleviciene Z, Gyllensten U, Haws ALF, Helland A, Herrington CS, Hildesheim A, Humbey O, Jee SH, Kim JW, Madeleine MM, Menczer J, Ngan HYS, Nishikawa A, Niwa Y et al. (2009)
   TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies
   Lancet Oncol., 10 (8), 772-784
   DOI 10.1016/S1470-2045(09)70187-1
7. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB (2009)
   Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis
   4 (5), e5583
   DOI 10.1371/journal.pone.0005583, PubMed 19440550
8. Potapenko IO, Haakensen VD, Lüders T, Helland A, Bukholm I, Sørlie T, Kristensen VN, Lingjaerde OC, Børresen-Dale AL (2009)
   Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression
   4 (2), 98-118
   DOI 10.1016/j.molonc.2009.12.001, PubMed 20060370
9. Selzer-Plon J, Bornholdt J, Friis S, Bisgaard HC, Lothe IM, Tveit KM, Kure EH, Vogel U, Vogel LK (2009)
   Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis
   9, 201
   DOI 10.1186/1471-2407-9-201, PubMed 19555470
10. Skovbjerg H, Anthonsen D, Lothe IM, Tveit KM, Kure EH, Vogel LK (2009)
    Collagen mRNA levels changes during colorectal cancer carcinogenesis
    9, 136
    DOI 10.1186/1471-2407-9-136, PubMed 19422682

Publications 2008

1. Saebø M, Skjelbred CF, Brekke Li K, Bowitz Lothe IM, Hagen PC, Johnsen E, Tveit KM, Kure EH (2008)
   CYP1A2 164 A-->C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas
   28 (4C), 2289-95
   PubMed 18751408

Publications 2007

1. Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA (2007)
   Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
   110 (6), 1264-71
   DOI 10.1002/cncr.22918, PubMed 17647260
2. Edvardsen H, Kristensen VN, Grenaker Alnaes GI, Bøhn M, Erikstein B, Helland A, Børresen-Dale AL, Fosså SD (2007)
   Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy
   67 (4), 1163-71
   DOI 10.1016/j.ijrobp.2006.11.009, PubMed 17336217
3. Lorentzen A, Vogel LK, Lewinsky RH, Saebø M, Skjelbred CF, Godiksen S, Hoff G, Tveit KM, Lothe IM, Ikdahl T, Kure EH, Mitchelmore C (2007)
   Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma
   7, 192
   DOI 10.1186/1471-2407-7-192, PubMed 17935612
4. Sikkeland LI, Haug T, Stangeland AM, Flatberg G, Søstrand P, Halvorsen B, Kongerud J (2007)
   Airway inflammation in paper mill workers
   49 (10), 1135-42
   DOI 10.1097/JOM.0b013e31814b2e87, PubMed 18000418
5. Sikkeland LI, Kongerud J, Stangeland AM, Haug T, Alexis NE (2007)
   Macrophage enrichment from induced sputum
   62 (6), 558-9
   DOI 10.1136/thx.2006.073544, PubMed 17536036
6. Skjelbred CF, Saebø M, Hjartåker A, Grotmol T, Hansteen IL, Tveit KM, Hoff G, Kure EH (2007)
   Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas
   7, 228
   DOI 10.1186/1471-2407-7-228, PubMed 18093316

Publications 2006

1. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006)
   Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers
   3 (3), e47
   DOI 10.1371/journal.pmed.0030047, PubMed 16417408
2. Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G (2006)
   Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
   118 (11), 2877-81
   DOI 10.1002/ijc.21709, PubMed 16381016
3. Helland A, Johnsen H, Frøyland C, Landmark HB, Saetersdal AB, Holmen MM, Gjertsen T, Nesland JM, Ottestad W, Jeffrey SS, Ottestad LO, Rodningen OK, Sherlock G, Børresen-Dale AL (2006)
   Radiation-induced effects on gene expression: an in vivo study on breast cancer
   80 (2), 230-5
   DOI 10.1016/j.radonc.2006.07.007, PubMed 16890317
4. Rzyman W, Hagen OM, Dziadziuszko R, Kobierska-Gulida G, Karmolinski A, Lothe IM, Babovic A, Murawski M, Paleczka W, Jastrzebski T, Kopacz A, Jassem J, Lass P, Skokowski J (2006)
   Intraoperative, radio-guided sentinel lymph node mapping in 110 nonsmall cell lung cancer patients
   Ann. Thorac. Surg., 82 (1), 237-242
   DOI 10.1016/j.athoracsur.2006.01.094
5. Saebø M, Skjelbred CF, Nexø BA, Wallin H, Hansteen IL, Vogel U, Kure EH (2006)
   Increased mRNA expression levels of ERCC1, OGG1 and RAI in colorectal adenomas and carcinomas
   6, 208
   DOI 10.1186/1471-2407-6-208, PubMed 16914027
6. Sarebø M, Skjelbred CF, Breistein R, Lothe IM, Hagen PC, Bock G, Hansteen IL, Kure EH (2006)
   Association between cigarette smoking, APC mutations and the risk of developing sporadic colorectal adenomas and carcinomas
   6, 71
   DOI 10.1186/1471-2407-6-71, PubMed 16545110
7. Skjelbred CF, Saebø M, Nexø BA, Wallin H, Hansteen IL, Vogel U, Kure EH (2006)
   Effects of polymorphisms in ERCC1, ASE-1 and RAI on the risk of colorectal carcinomas and adenomas: a case control study
   6, 175
   DOI 10.1186/1471-2407-6-175, PubMed 16817948
8. Skjelbred CF, Saebø M, Wallin H, Nexø BA, Hagen PC, Lothe IM, Aase S, Johnson E, Hansteen IL, Vogel U, Kure EH (2006)
   Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study
   6, 67
   DOI 10.1186/1471-2407-6-67, PubMed 16542436
9. Stormorken AT, Hoff G, Norstein J, Bowitz-Lothe IM, Hanslien E, Grindedal E, Møller P (2006)
   Estimated prevalence of hereditary cancers and the need for surveillance in a Norwegian county, Telemark
   41 (1), 71-9
   DOI 10.1080/00365520510023891, PubMed 16373279
10. Vogel LK, Saebø M, Skjelbred CF, Abell K, Pedersen ED, Vogel U, Kure EH (2006)
    The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals
    6, 176
    DOI 10.1186/1471-2407-6-176, PubMed 16820046

Publications 2005

1. Hansen R, Saebø M, Skjelbred CF, Nexø BA, Hagen PC, Bock G, Bowitz Lothe IM, Johnson E, Aase S, Hansteen IL, Vogel U, Kure EH (2005)
   GPX Pro198Leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer
   229 (1), 85-91
   DOI 10.1016/j.canlet.2005.04.019, PubMed 15946795
2. Stormorken AT, Bowitz-Lothe IM, Norèn T, Kure E, Aase S, Wijnen J, Apold J, Heimdal K, Møller P (2005)
   Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary nonpolyposis colorectal cancer
   23 (21), 4705-12
   DOI 10.1200/JCO.2005.05.180, PubMed 16034045
3. Wang Y, Helland A, Holm R, Kristensen GB, Børresen-Dale AL (2005)
   PIK3CA mutations in advanced ovarian carcinomas
   25 (3), 322
   DOI 10.1002/humu.9316, PubMed 15712344
4. Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R (2005)
   Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
   124 (3), 392-401
   DOI 10.1309/BL7E-MW66-LQX6-GFRP, PubMed 16191507

Publications 2004

1. Soucek P, Skjelbred CF, Svendsen M, Kristensen T, Kure EH, Kristensen VN (2004)
   Single-track sequencing for genotyping of multiple SNPs in the N-acetyltransferase 1 (NAT1) gene
   4, 28
   DOI 10.1186/1472-6750-4-28, PubMed 15563733
2. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A (2004)
   Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
   24 (1), 21-34
   DOI 10.1002/humu.20055, PubMed 15221786

Publications 2003

1. Kristiansen M, Helland A, Kristensen GB, Olsen AO, Lønning PE, Børresen-Dale AL, Ørstavik KH (2003)
   X chromosome inactivation in cervical cancer patients
   146 (1), 73-6
   DOI 10.1016/s0165-4608(03)00152-3, PubMed 14499700
2. Stormorken AT, Müller W, Lindblom A, Heimdal K, Aase S, Lothe IM, Norèn T, Wijnen JT, Möslein G, Møller P (2003)
   The inframe MSH2 codon 596 deletion is linked with HNPCC and associated with lack of MSH2 protein in tumours
   2 (1), 9-13
   DOI 10.1023/a:1023362205205, PubMed 14574162

Publications 2001

1. Kristensen VN, Kure EH, Erikstein B, Harada N, Børresen-Dale A (2001)
   Genetic susceptibility and environmental estrogen-like compounds
   482 (1-2), 77-82
   DOI 10.1016/s0027-5107(01)00212-3, PubMed 11535251

Publications 2000

1. Skaug V, Ryberg D, Kure EH, Arab MO, Stangeland L, Myking AO, Haugen A (2000)
   p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients
   6 (3), 1031-7
   PubMed 10741731

Publications 1997

1. Hollstein M, Bartsch H, Wesch H, Kure EH, Mustonen R, Mühlbauer KR, Spiethoff A, Wegener K, Wiethege T, Müller KM (1997)
   p53 gene mutation analysis in tumors of patients exposed to alpha-particles
   18 (3), 511-6
   DOI 10.1093/carcin/18.3.511, PubMed 9067550

Publications 1996

1. Andreassen A, Kure EH, Nielsen PS, Autrup H, Haugen A (1996)
   Comparative synchronous fluorescence spectrophotometry and 32P-postlabeling analysis of PAH-DNA adducts in human lung and the relationship to TP53 mutations
   368 (3-4), 275-82
   DOI 10.1016/s0165-1218(96)90069-5, PubMed 8692233

Publications 1995

1. Ovrebø S, Fjeldstad PE, Grzybowska E, Kure EH, Chorazy M, Haugen A (1995)
   Biological monitoring of polycyclic aromatic hydrocarbon exposure in a highly polluted area of Poland
   103 (9), 838-43
   DOI 10.1289/ehp.103-1519226, PubMed 7498096

Publications 1994

1. RYBERG D, KURE E, LYSTAD S, SKAUG V, STANGELAND L, MERCY I, BORRESEN AL, HAUGEN A (1994)
   P53 MUTATIONS IN LUNG-TUMORS - RELATIONSHIP TO PUTATIVE SUSCEPTIBILITY MARKERS FOR CANCER
   Cancer Res., 54 (6), 1551-1555
2. Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, Børresen AL, Haugen A (1994)
   p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer
   54 (6), 1551-5
   PubMed 8137262

Publications 1991

1. Rappaport SM, Kure E, Petreas M, Ting D, Woodlee J (1991)
   A field method for measuring solvent vapors in exhaled air--application to styrene exposure
   17 (3), 195-204
   DOI 10.5271/sjweh.1710, PubMed 2068559